Pirfenidone

Treatment for Interstitial lung disease and pulmonary sarcoidosis

Typical Dosage: 2403 mg daily

Effectiveness
65%
Safety Score
40%
Clinical Trials
1
Participants
2.5K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
40
DangerousModerateSafe
Treatment Details
Dosage Range
2403 mg daily
Time to Effect
3-6 months (sustained effect)
Treatment Duration
Lifetime
Evidence Quality
HIGH
Number Needed to Treat (NNT)
9(Treat 9 patients to see 1 additional successful outcome)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$7,500
Monitoring:$1,500
Side Effect Mgmt:$1,000
Total Annual:$10,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POOR
ICER
$250,000/QALY
QALYs Gained
0.2
Outcome-Based Costs
Cost per Responder
$18,182
Pirfenidone Outcomes

for Interstitial lung disease and pulmonary sarcoidosis

Efficacy Outcomes
Overall Effectiveness
+65%
Response Rate
+55%
Common Side Effects
Nausea
+35%
Diarrhea
+25%
Photosensitivity
+15%
Rash
+15%
Liver enzyme elevation
+10%

Sources:

researchgate.net
atsjournals.org
mdpi.com

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

FIX IT
Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov